The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

Imfinzi recommended for approval in European Union for the treat of adults with limited-stage small cell lung cancer ...

Antibody Drug Conjugates Market Market Growth Fueled by Advancements in ADC Technology, Increased Demand for Targeted Cancer Therapies, and ...

In addition to revenue growth, AstraZeneca's core earnings per share climbed 44% to $2.09. Research and development spending ...

Shares of solid tumor concern Zymeworks Inc. have barely budged since the company obtained its first approval. Click here to read why ZYME stock is a Hold.

The FDA approves AstraZeneca's sBLA for Enhertu to treat HER2-low or HER2 ... factor receptor-mutated (EGFR-mutated) non-small cell lung cancer (NSCLC) who have received prior systemic therapies ...

Enhertu was given accelerated approval for ... second-line therapy for HER2-altered NSCLC at the World Conference on Lung Cancer (WCLC) in San Diego on 9th September. Bayer’s push to become ...

and lung cancer, as well as a tumour-agnostic indication for HER2-positive tumours. Enhertu had worldwide sales of more than $2.7 billion in the first nine months of 2024, up from $1.8 billion in ...

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

Given the evolving role of trastuzumab deruxtecan (Enhertu) in the treatment of breast cancer, especially those who are HER2 positive, staying vigilant in looking for signs of adverse events (AEs) is ...